Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
NCT05696483Phase 1Active, not recruiting
- Sponsor
- Oligomerix
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OLX-07010 in Alzheimer's disease (AD) (2 arms), sponsored by Oligomerix. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 30 days. Started Jan 2023; status: active, not recruiting.
02
Drugs
OLX-07010
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05696483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696483.